Prostate cancer drug trialed to reduce steroids in kids with rare hormone disorder

NCT ID NCT02574910

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a drug called abiraterone acetate (normally used for prostate cancer) in 4 children with congenital adrenal hyperplasia (CAH). The goal was to see if it could lower high male hormone levels and reduce the need for strong steroid medications that can slow growth. The study was stopped early because not enough children signed up, so no clear conclusions could be drawn.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency congenital adrenal hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Hospital of Los Angeles

    Los Angeles, California, 90027, United States

  • Children's Medical Center

    Dallas, Texas, 75235, United States

  • National Institutes of Health

    Bethesda, Maryland, 20892-1932, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States